ISPOR Europe 2022: from pipeline assets to patient access

We’ll be at the ISPOR Europe exhibition in Vienna, on 6–9 November 2022. Come and meet, Policy Analysis Inc. (PAI) and PRMA Consulting for the latest news about our end‑to‑end Policy, Access, Value, and Evidence services

Showcasing end-to-end Policy, Access, Value, and Evidence, services at ISPOR Europe 2022

PAI and PRMA Consulting, members of Fishawack Health, are looking forward to attending ISPOR Europe 2022 to showcase our combined Policy, Access, Value, and Evidence (PAVE) services.  

“It’s fantastic to see the return of the ISPOR Europe in-person conference,” says Gerry Oster, PAI Scientific Lead & Fishawack Health Global Head of Health Economics, “and I am looking forward to sharing how our Policy, Access, Value, and Evidence capabilities will help delegates accelerate the time it takes to achieve market access for their assets.” 


Engaging our collective force to accelerate your HEOR, market access, and commercialization decisions

In a rapidly evolving environment where stakeholders are becoming more evidence hungry and value aware, we provide best-in-class data-driven solutions to complex healthcare challenges.  

Our Policy, Access, Value, and Evidence consultancy delivers policy, market access, HEOR, and value engagement solutions for global, regional, and local stakeholders in the US, Europe, APAC, and LatAm.   

As a member of Fishawack Health, we are empowered by data, innovative digital applications, and experienced-based insights that accelerate time to patient access for your assets. We partner with clients who span the healthcare continuum including leading biopharma and life sciences companies. 


Book your demonstration of digital solutions for HEOR and market access at ISPOR Europe 2022

ISPOR 2022 provides the perfect opportunity to examine the digital transformation of your market access process.

Experts from PAI and PRMA Consulting, members of Fishawack Health, will be available on booths X2 204–205 to aid you in evaluating how our digital applications will help you realize and accelerate your market access vision.

With the rapidly evolving HEOR and market access landscape, we are now on the cusp of a huge acceleration in the use of digital applications to explore value options, gain strategic advantage, and provide innovative market access solutions. It’s inevitable that digital applications will be used within HEOR and market access.


Book a live demonstration of our HEOR and Market Access digital solutions at ISPOR Europe 2022, booths X2 204205

hēRo3 has revolutionized HEOR modeling, especially for pipeline assets, enabling rapid value analytics to be conducted for development candidates. In turn, it plays a key role in promoting the strategic design of clinical development programs and HEOR evidence generation plans. The novel technology is used by more than a dozen of the top 40 biopharmaceutical companies and has helped usher in an era of rapid HEOR analytics for pipeline assets. Book a live demonstration at ISPOR Europe.
PRMA Healthcheck® helps you to maximize the value of your asset portfolio at all stages of development. It drives a systematic and robust assessment of the market access risks and opportunities based on treatment landscapes, pricing potential, and evolving payer needs. Book a live demonstration at ISPOR Europe.
PRMA Navigator® helps you empower your affiliates to efficiently and effectively deliver high-quality multiple HTA and other payer submissions by maximizing the use of global materials, saving time and resources to focus on getting the strategy right. Book a live demonstration at ISPOR Europe.
PRMA Tracker® tracks the evolving HTA and P&R landscape for key competitors or products of interest to ensure key learnings from payer assessments are captured and the strategic implications for your asset are considered. 
Book a live demonstration at ISPOR Europe.

FREE Ebook

Reinventing product and portfolio value for the biopharmaceutical industry

We respect your privacy. Cookie policy.

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...